Literature DB >> 2942599

Comparison of the immunogenicity, efficacy and safety of 10 micrograms and 20 micrograms of a hepatitis B vaccine: a prospective randomized trial.

E K Yeoh, C L Lai, W K Chang, H Y Lo.   

Abstract

Four thousand and one hospital staff were screened for hepatitis B virus (HBV) markers in a vaccination programme in Hong Kong. The seropositivity rate for HBsAg, anti-HBs and anti-HBc were significantly higher in the 3160 existing hospital staff than in 841 new recruits. Of the subjects negative for HBV markers, 605 were randomized to receive three doses of either 10 or 20 micrograms of the Merck Institute vaccine (HB-VAX). Compared with the 20 micrograms dose, vaccination with the 10 micrograms dose results in equal immunogenicity and efficacy at the completion of the three injections but induced a slower response rate and lower anti-HBs titres with the first two doses. The commonest side-effect of local soreness was less with the 10 micrograms dose. We conclude that (1) hospital staff working in high endemic areas should be vaccinated on recruitment and (2) the 10 micrograms dose of HB-VAX can replace the recommended 20 micrograms dose for adults, being cheaper and as efficacious.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942599      PMCID: PMC2129698          DOI: 10.1017/s0022172400066298

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  11 in total

1.  Hepatitis B virus infection in dentists.

Authors:  J W Mosley; V M Edwards; G Casey; A G Redeker; E White
Journal:  N Engl J Med       Date:  1975-10-09       Impact factor: 91.245

2.  Immune responses to active and passive-active vaccination against hepatitis B.

Authors:  F Deinhardt; R Zachoval; W Jilg; B Lorbeer; M Roggendorf
Journal:  J Infect       Date:  1983-07       Impact factor: 6.072

3.  Reduction of the dose of hepatitis B vaccine.

Authors:  G Papaevangelou; A Roumeliotou-Karayannis; C Vissoulis; P Stathopoulou; N Kolaitis; S Krugman
Journal:  J Infect       Date:  1983-07       Impact factor: 6.072

4.  The immune response of healthy Nigerian adults to small doses of hepatitis B vaccine: comparison of 10- and 20-micrograms doses.

Authors:  E A Ayoola
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

5.  Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 microgram and 40 microgram doses.

Authors:  S Krugman; H P Holley; M Davidson; M S Simberkoff; N Matsaniotis
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

6.  Purified and inactivated human hepatitis B vaccine: progress report.

Authors:  M R Hilleman; E B Buynak; R R Roehm; A A Tytell; A U Bertland; G P Lampson
Journal:  Am J Med Sci       Date:  1975 Sep-Oct       Impact factor: 2.378

7.  Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA.

Authors:  E M Scolnick; A A McLean; D J West; W J McAleer; W J Miller; E B Buynak
Journal:  JAMA       Date:  1984-06-01       Impact factor: 56.272

8.  Human hepatitis B vaccine from recombinant yeast.

Authors:  W J McAleer; E B Buynak; R Z Maigetter; D E Wampler; W J Miller; M R Hilleman
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

9.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more
  1 in total

Review 1.  Adverse events after hepatitis B vaccination.

Authors:  P Duclos
Journal:  CMAJ       Date:  1992-10-01       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.